IL1B and inflammation: IL-1β inhibition, as demonstrated in the CANTOS trial, has shown significant reductions in cardiovascular events in high-risk patients, suggesting that IL-1β blockade could also be beneficial in trauma patients with persistent myocardial inflammation.